[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625298":3},{"organization":4,"armGroups":7,"interventions":36,"overallOfficials":41,"centralContacts":57,"locations":63,"responsibleParty":83,"collaborators":41,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":87,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":41,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":41,"overallStatus":66,"whyStopped":41,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Apsen Farmaceutica S.A.","INDUSTRY",[8,14,18,22,26,31],{"label":9,"type":10,"description":11,"interventionNames":12},"APSTZD 1","EXPERIMENTAL","5 oral tablets, once a day, before bedtime, for 6 weeks.",[13],"Drug: APSTZD 1",{"label":15,"type":10,"description":11,"interventionNames":16},"APSTZD 2",[17],"Drug: APSTZD 2",{"label":19,"type":10,"description":11,"interventionNames":20},"APSTZD 3",[21],"Drug: APSTZD 3",{"label":23,"type":10,"description":11,"interventionNames":24},"APSTZD 4",[25],"Drug: APSTZD 4",{"label":27,"type":28,"description":11,"interventionNames":29},"Stilnox CR®","ACTIVE_COMPARATOR",[30],"Drug: Stilnox CR®",{"label":32,"type":33,"description":11,"interventionNames":34},"Placebo","PLACEBO_COMPARATOR",[35],"Drug: Placebo",[37,42,45,48,51,54],{"type":38,"name":9,"description":39,"armGroupLabels":40,"otherNames":41},"DRUG","APSTZD + placebo test 2 + placebo test 3 + placebo test 4 + comparator placebo 1",[9],null,{"type":38,"name":15,"description":43,"armGroupLabels":44,"otherNames":41},"APSTZD + placebo test 1 + placebo test 3 + placebo test 4 + comparator placebo 1",[15],{"type":38,"name":19,"description":46,"armGroupLabels":47,"otherNames":41},"APSTZD + placebo test 1 + placebo test 2 + placebo test 4 + comparator placebo 1",[19],{"type":38,"name":23,"description":49,"armGroupLabels":50,"otherNames":41},"APSTZD + placebo test 1 + placebo test 2 + placebo test 3 + comparator placebo 1",[23],{"type":38,"name":27,"description":52,"armGroupLabels":53,"otherNames":41},"Stilnox CR® + placebo test 1 + placebo test 2 + placebo test 3 + placebo test 4",[27],{"type":38,"name":32,"description":55,"armGroupLabels":56,"otherNames":41},"placebo test 1 + placebo test 2 + placebo test 3 + placebo test 4 + comparator 1",[32],[58],{"name":59,"role":60,"phone":61,"phoneExt":41,"email":62},"Bianca Zanetti","CONTACT","+55115641-2305","bianca.zanetti@apsen.com.br",[64],{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"UNIFAG - Casa Nossa Senhora da PAZ -ASF","RECRUITING","Bragança Paulista","São Paulo","12916-900","Brazil","BR",{"type":73,"coordinates":74},"Point",[75,76],-46.54418,-22.9527,{"lat":76,"lon":75},[79],{"name":80,"role":60,"phone":81,"phoneExt":41,"email":82},"Rafaella Santos Dantas Beltrame","+55(35)98833-9715","rafaellasantosdantas@gmail.com",{"type":84,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100625298","phase-2-efficacy-and-safety-of-apstzd-in-the-treatment-of-insomnia-disorder-100625298",false,"NCT07420816","Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder","Phase II Randomized, Multicenter, Double-blind, Doubledummy, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder","TINA","Inclusion Criteria:\n\n* Participants aged between 18 and 64 years;\n* Participants diagnosed with insomnia disorder according to the criteria defined by the DSM-V (1) and who report sleep maintenance disorder;\n* Participants who agree not to use alcoholic beverages during the entire treatment period (6 weeks).\n\nExclusion Criteria:\n\n* Participants with known hypersensitivity to the active ingredients used during the trial or who have exhibited complex sleep behavior after using them;\n* Participants with a history of alcohol, substance, or illicit drug abuse disorder in the last 2 years;\n* Women who are pregnant or breastfeeding, as well as women who have a positive result on a pregnancy test (β-hCG) during the screening period of the trial;\n* Participants diagnosed with severe liver failure;","ALL","18 Years","64 Years",{"count":97,"type":98},222,"ESTIMATED","INTERVENTIONAL",[101],"PHASE2","The purpose of this study is to evaluate the efficacy of APSTZD compared to one active drug and placebo in insomnia treatment.",[104,105],"Insomnia","Insomnia Chronic","2026-08-20",{"date":108,"type":109},"2026-08-21","ACTUAL",{"date":111,"type":109},"2026-08-05",{"date":113,"type":98},"2027-12",{"name":5,"class":6},1]